Skip to main content

Table 1 Baseline characteristics of subjects in genetic sub-study of CORONA

From: The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)

Characteristics of patients

n  = 3,320

Age (years)

72.3 ± 6.9

Males n (%)

2530 (76.2)

Left ventricular ejection fraction (% ± SD)

31 ± 6.3

NYHA class n (%)

 

II

1251 (37.7)

III

2035 (61.3)

IV

34 (1.0)

History of n (%)

 

Angina Pectoris

2463 (74.2)

Aortic Aneurysm

84 (2.5)

Aortic Aneurysm Surgery Performed

47 (1.4)

Atrial Fibrillation/Flutter

1318 (39.7)

Diabetes Mellitus

933 (28.1)

Hypertension

2173 (65.5)

Implantable cardioverter-defibrillator

79 (2.4)

Implanted pacemaker

349 (10.5)

Intermitted claudication

392 (11.8)

Myocardial infarction

1986 (59.8)

Coronary Artery Bypass Surgery

537 (16.2)

Percutaneous Coronary Intervention

358 (10.8)

CABG or PCI

823 (24.8)

Stroke

386 (11.6)

Smoking status n (%)

 

Non Smoker

1521 (45.8)

(Ex-)smoker

1797 (54.1)

Heart Failure Medication at baseline n (%)

 

Loop diuretic

2421 (72.9)

Thiazide diuretic

776 (23.4)

Loop or Thiazide

2879 (86.7)

Beta-Blocker

2542 (76.6)

ACE inhibitor

2696 (81.2)

AT1-receptor blocker

428 (12.9)

ACE inhibitor or AT1-receptor blocker

3063 (92.3)

Aldosterone antagonist

1284 (38.7)

Digitalis

1072 (32.3)

Anti-platelet or Anti-coagulant

3020 (91.0)

Blood pressure (mmHg)

 

Systolic

130.5 ± 16.1

Diastolic

77.0 ± 8.6

Heart rate (beats/min)

71.2 ± 10.9

BMI (kg/m2)

27.5 ± 4.4

Serum creatinine (umol/L)

112.8 ± 26.5

eGFR (ml/min/1.73 m/m2BSA)

58.5 ± 14.0

hs-CRP (mg/L)

3.3 (0.02-230)

NT-proBNP (pmol/L)

151 (1–3868)

Lipids

 

Total cholesterol (mmol/L)

5.41 ± 1.07

LDL-cholesterol (mmol/L)

3.60 ± 0.94

HDL-cholesterol (mmol/L)

1.19 (0.47-3.55)

Apo-A1 (g/L)

1.51 ± 0.27

Apo-B (g/L)

1.28 ± 0.30

Apo-B/Apo-A (mean)

0.87 ± 0.24

Triglycerides (mmol/L)

1.68 (0.41-14.43)

  1. Abbreviations: NYHA New York Heart Association, CABG Coronary Artery Bypass Graft, PCI Percutaneous Coronary Intervention, ACE Acetylcholinesterase, AT1 Angiotensin-1, BMI body mass index, eGFR estimated Glomerular Filtration Rate, hs-CRP high sensitive C-reactive protein, NT-proBNP N-terminal pro B-type natriuretic peptide, LDL low-density lipoprotein, HDL high-density lipoprotein, Apo apolipoprotein. Variables are expressed as mean (SD) when normally distributed and as median (min-max) when non-normally distributed.